Raffles Medical Group Likely Entering Stronger Growth Phase -- Market Talk

Dow Jones
02/24

0318 GMT - Raffles Medical Group is likely entering a stronger growth phase in 2026-2027, RHB Research's Shekhar Jaiswal says in a report. The recovery in its Singapore-based hospitals may extend on specialist-led volumes and supportive insurer-panel flow, while the losses at its China-based clinics could continue to narrow, the analyst says. The Singapore-listed healthcare provider's margins should also remain resilient on measured price increases and tech-driven productivity gains, offsetting wage inflation. RHB Research raises the stock's target price to S$1.30 from S$1.15 to reflect a valuation rollover, with its buy rating unchanged. Shares are 0.9% higher at S$1.08. (ronnie.harui@wsj.com)

 

(END) Dow Jones Newswires

February 23, 2026 22:18 ET (03:18 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10